3 hrs ago
Wall Street set to open flat
US stocks were set for a flat open on Tuesday after a slight decline in the prior session left the S&P 500 within striking distance of its recent record high and amid investor caution as tensions in Ukraine continued.
Trending on the Topix Network
4 hrs ago
Investor's Business Daily
Stocks Futures Effectively Flat; Boyd Gaming Up, Myriad Dives
Dow futures backed out of thin, early gains and were a mild 2.7 points below fair market value.
10 hrs ago
Press Digest- New York Times business news - March 11
The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy.
Mon Mar 10, 2014
USPTO Guidance for Examiners Takes Expansive View of Myriad and Prometheus Decisions
On March 4, 2014, the U.S. Patent and Trademark Office issued a memorandum to the Patent Examining Corps with guidance for determining the patent eligibility of claims relating to products of nature and laws of nature in view of the U.S. Supreme Court decisions in Assoc.
Sat Mar 08, 2014
USPTO Issues Guidance for Examining Process Patents
On March 4th, 2014, the U.S. Patent and Trademark Office issued " 2014 Procedures For Subject Matter Eligibility Analysis Of Claims Reciting Or Involving Laws of Nature/Natural Principles, Natural Phenomena, And/Or Natural Products" Guidance , advising examiners and the public of the factors for determining whether an invention satisfies the U.S.
Fri Mar 07, 2014
Mayo, Myriad, and Multi-factor balancing tests
On the same day that the Supreme Court's opinion was handed down in Assoc. for Mol.
The Motley Fool
The Nasdaq's 5 Most Hated Stocks
I actually had to do some digging to come up with the date of April 7, 2000 as the last time the technology-heavy Nasdaq Composite closed at a higher point than it did earlier this week.
Thu Mar 06, 2014
USPTO to Apply Myriad Beyond Isolated DNA
Today, the United States Patent and Trademark Office issued a Guidance , advising examiners and the public of the factors for determining whether an invention satisfies the U.S. Supreme Court's interpretation of 35 U.S.C. A 101, as applied to patent-eligibility.
Mon Mar 03, 2014
Myriad publishes clinical utility study for Prolaris
Myriad Genetics, Inc. today announced that it has published data from the PROCEDE 500 study in the journal Current Medical Research and Opinion , demonstrating that 65 percent of physicians changed their original treatment plans for men with prostate cancer based on results from the Prolaris test.
Wed Feb 26, 2014
Myriad Genetics Director Walter Phd Gilbert Unloads 30,000 Shares
Myriad Genetics Director Walter Phd Gilbert unloaded 30,000 shares of the stock in a transaction dated Wednesday, February 26th.
Fri Feb 21, 2014
Recently released market study: Crescendo Bioscience, Inc. - Medical...
It develops quantitative, objective, and biology based tests to provide rheumatologists with deeper clinical insights to enable more effective management of patients with autoimmune and inflammatory diseases.
Thu Feb 20, 2014
Medical News Today
Data shows Prolaris test predicts metastases in prostate cancer from biopsies
Myriad Genetics, Inc. has announced it has published data in the Journal of Urology demonstrating that its Prolaris test accurately predicted, based on biopsy specimens, which men would develop biochemical recurrence or metastatic disease following radical prostate surgery.
Wed Feb 19, 2014
Five Star Equities Issues New Research Reports on CCIH, CMLS, LTBR...
Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns.
Tue Feb 18, 2014
Patent infringement lawsuit over breast cancer testing genes settled this month
Gene by Gene, Ltd. and Myriad Genetics, Inc., along with the University of Utah Research Foundation, HSC Research and Development Limited Partnership, Endorecherche, Inc. and the Trustees of the University of Pennsylvania announced on Feb. 7 that they reached an agreement in a lawsuit pertaining to patents for BRCA1 and BRCA2, two genes that can ... (more)
The Motley Fool
Why Myriad Genetics, Chindex International, and JA Solar Soared Today
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.
Myriad Genetics: 5 Different Insiders Have Sold Shares This Month
In this article, I will feature one services sector stock that has seen intensive insider selling during the last 30 days.
Fri Feb 14, 2014
New Stocks Make Most Attractive/Dangerous Lists For February
Our Most Attractive and Most Dangerous stocks for February were made available to the public at midnight on Wednesday.
Wed Feb 12, 2014
Myriad Still Cheap After Steep Climb, Southwest Stock Dangerously High
Each month I put together a dozen or so stocks that I call ' most attractive,' and another dozen ' dangerous' stocks.
Tue Feb 11, 2014
Zocere Appoints Zavitz as Chief Scientific Officer
Zocere is developing an injectable neuroprotectant drug designed to combat brain injury resulting from stroke and other head trauma such as concussion.